4.8 Article

Growth hormone enhances thymic function in HIV-1-infected adults

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 118, Issue 3, Pages 1085-1098

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI32830

Keywords

-

Funding

  1. NCRR NIH HHS [RR00083-44, M01 RR00083, M01 RR000083] Funding Source: Medline
  2. NIAID NIH HHS [P30 AI027763, R21 AI062457, AI01597, AI47062, AI40312, R01 AI047062, U01 AI043864, R37 AI040312, R01 AI043864, AI43864, AI062457, R01 AI040312] Funding Source: Medline
  3. NIH HHS [DPI OD00329, DP1 OD000329] Funding Source: Medline
  4. NIMH NIH HHS [P30 MH59037] Funding Source: Medline

Ask authors/readers for more resources

Growth hormone (GH) is an underappreciated but important regulator of T cell development that can reverse age-related declines in thymopoiesis in rodents. Here, we report findings of a prospective randomized study examining the effects of GH on the immune system of HIV-1-infected adults. GH treatment was associated with increased thymic mass. In addition, GH treatment enhanced thymic output, as measured by both the frequency of T cell receptor rearrangement excision circles in circulating T cells and the numbers of circulating naive and total CD4(+) T cells. These findings provide compelling evidence that GH induces de novo T cell production and may, accordingly, facilitate CD4(+) T cell recovery in HIV-1-infected adults. Further, these randomized, prospective data have shown that thymic involution can be pharmacologically reversed in humans, suggesting that immune-based therapies could be used to enhance thymopoiesis in immunodeficient individuals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available